Chemotherapy options in ovarian carcinoma — a dose intensity perspective

  • L. Levin


Ovarian carcinoma is a moderately chemosensitive tumour and since most patients present with advanced disease, attention continues to be focused on new systematic treatment initiatives. Comparisons between clinical trial outcomes in ovarian carcinoma have in the past been made difficult as a result of differences between populations studied, variations in sample size which has affected the statistical power to compare two or more treatment arms, and inattention or inability to account for variations in drug doses between studies.


Ovarian Cancer Single Agent Ovarian Carcinoma Median Survival Time Dose Intensity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levin, L. and Hryniuk, W.M. (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 5, 756–67.PubMedGoogle Scholar
  2. 2.
    Ozols, R.F., Corden, B.J., Jacob, J. et al. (1984) High dose cisplatinum in hypertonic saline. Ann. Intern. Med 100,19–24.PubMedGoogle Scholar
  3. 3.
    Ngan, H.Y.S., Choc, Y.C., Cheung, M. et al (1989) A randomized study of high dose vs low-dose cisplatinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35, 221–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Kaye, S.B., Lewis, C.R., Paul, J. et al (1992) Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340,329–33.PubMedCrossRefGoogle Scholar
  5. 5.
    McGuire, W.P., Hoskins, W.J., Brady, M.F. et al (1992) A phase III trial of dose intense (DI) vs standard dose (DS) cisplatin (CDDP) and Cytoxan (CTX) in advanced ovarian cancer (AOC). Proc. Am. Sac. Clin. Oncol 11, A718.Google Scholar
  6. 6.
    Boni, C., Cocconi, G., Lottici, R. et al (1990) Conventional vs high dose intensity cisplatin in advanced ovarian cancer. Preliminary report of a randomized trial. Proc. Am. Soc. Clin. Oncol 9 A651.Google Scholar
  7. 7.
    Colombo, N., Pittelli, M.R., Marzola, M. et al (1990) Randomized study of two cisplatin (P) dose intensity regimens in patients with stage III/IV epithelial ovarian cancer (HOC). Proc. Am. Soc. Clin. Oncol 9 A619.Google Scholar
  8. 8.
    Jacobs, A.J., Sommers, G.M., Homan, S.M. et al (1988) Therapy of ovarian carcinoma: the relationship of dose level and treatment intensity to survival. Gynecol Oncol 31, 233–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Levin, L. (1993) Dose intensity in the treatment of ovarian carcinoma. In Cancer of the Ovary (eds M. Markman and W.J. Hoskins), Raven Press, New York, pp. 251–60.Google Scholar
  10. 10.
    Hunter, R.W., Alexander, N.D.E. and Soutter, W.P. (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol 166, 504–11.PubMedGoogle Scholar
  11. 11.
    Levin, L., Simon, R. and Hryniuk, W.M. (1993) The importance of multiagent chemotherapy regimens in ovarian carcinoma - dose intensity analysis, J. Natl Cancer Inst 85,1732–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Ovarian Cancer Meta-Analysis Project (1991) Cyclophosphamide plus cisplatin vs cyclophosphamide, doxorubicin, and cisplatin chemotherapy in ovarian carcinoma: a metaanalysis. J. Clin. Oncol 9 1668–74.Google Scholar
  13. 13.
    Kankipati, S.R. and Wiltshaw, E. (1981) A prospective randomized study of cisplatinum as a single agent and in combination with chlorambucil in advanced ovarian carcinoma. Br. J. Cancer. 44, 289.Google Scholar
  14. 14.
    Tomirotti, M., Perrone, S., Gie, P. et al (1988) Cisplatin (P) vs cyclophosphamide, adri- amycin and cisplatin (CAP) for stage III/IV epithelial ovarian carcinoma: a prospective randomized trial. Turnori 74, 573–7.Google Scholar
  15. 15.
    Wiltshaw, E., Evans, B., Rustin, G. et al (1986) A prospective randomized trial comparing 17. high dose cisplatin with low dose cisplatin and chlorambucil in advanced ovarian carcinoma. J. Clin. Oncol 4, 722–9.PubMedGoogle Scholar
  16. 16.
    Gruppo Interegionale Cooperativo Oncologico Ginecologia (1987) Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/ cisplatin in advanced ovarian cancer. Lancet ii, 353–9.Google Scholar
  17. 17.
    Bruckner, H.W., Cohen, C.J., Goldberg, J.D. et al (1981) Improved chemotherapy for ovarian cancer with cis-diammine dichloro- platinum and adriamycin. Cancer 47, 2288–94.PubMedCrossRefGoogle Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • L. Levin

There are no affiliations available

Personalised recommendations